Grimaudo and colleagues followed 471 consecutive patients with histological diagnosis of MASLD or with clinical diagnosis of compensated MASLD‐related cirrhosis observing that in a median follow‐up time of 64 months the PNPLA3 rs738409 C > G variant was independently associated with a higher risk of developing liver decompensation both in the entire cohort and the subgroup of patients with F3 liver fibrosis or cirrhosis [73]. Here, PNPLA3 is linked to metabolic dysfunction-associated steatotic liver disease.